<DOC>
	<DOCNO>NCT00182364</DOCNO>
	<brief_summary>PROTECT Pilot objective ass : 1 ) feasibility timely enrollment complete , blind study drug administration , 2 ) bioaccumulation LMWH patient acquire renal insufficiency association bleeding , 3 ) feasibility schedule twice weekly low limb ultrasound , 4 ) recruitment rate future randomize trial .</brief_summary>
	<brief_title>PROphylaxis ThromboEmbolism Critical Care Trial ( PROTECT Pilot )</brief_title>
	<detailed_description>Prophylaxis Thromboembolism Critical Care Trial : PROTECT pilot Study Background : Critically ill patient increase risk deep venous thrombosis ( DVT ) due acute illness , procedures central venous catheterization , immobility due sedation paralysis . Among patient intensive care unit ( ICU ) , DVT important problem , since thrombus propagation embolization lead potentially fatal pulmonary embolism ( PE ) . Only 1 publish randomize trial ( n=119 ) medical-surgical ICU patient demonstrate unfractionated heparin ( UFH ) prevent DVT compare prophylaxis ; 1 publish randomize trial ( n=223 ) mechanically ventilated COPD patient show low molecular weight heparin ( LMWH ) prevent DVT compare prophylaxis . A trial compare LMWH UFH DVT prophylaxis medical-surgical ICU patient need . On one hand , LMWH likely effective VTE prevention associate low rate heparin-induced thrombocytopenia ( HIT ) . On hand , UFH likely associate low bleeding rate , less expensive . The necessity trial highlight fact UFH dominant method VTE prophylaxis critically ill patient Canada , whereas LMWH standard practice western Europe . Objectives : The scientific objective PROTECT determine effect LMWH versus UFH rate DVT , PE , bleeding , thrombocytopenia HIT medical-surgical ICU patient . The feasibility objective PROTECT Pilot ass : 1 ) feasibility timely enrollment complete , blind study drug administration , 2 ) bioaccumulation LMWH patient acquire renal insufficiency association bleeding , 3 ) feasibility schedule twice weekly low limb ultrasound , 4 ) recruitment rate future randomize trial . Design : Prospective , conceal , stratify , block randomize , blind , multicentre trial . Setting : Canadian medical-surgical university-affiliated ICUs . Inclusion criterion : Patients &gt; 18 year old anticipated ICU stay &gt; 72 hour . Exclusion criterion : Patients admit ICU post trauma , orthopedic surgery , cardiac surgery , neurosurgery , severe hypertension , DVT , PE major hemorrhage admission within 3 month , coagulopathy , thrombocytopenia , creatinine clearance &lt; 30ml/min , need therapeutic anticoagulation exclude . Patients document heparin allergy HIT , receipt &gt; 2 dos LMWH UFH ICU , contraindication heparin blood product , patient pregnant , undergo withdrawal life support , enrol related randomized trial also exclude . Methods : Using centralize telephone randomization , allocate 120 patient dalteparin 5,000 IU daily unfractionated heparin 5,000 IU twice daily subcutaneously . The ICU team research personnel blind study drug . Patients develop creatinine clearance &lt; 30 ml/min ICU trough anti-Xa heparin level ; result unavailable ICU team use blind dose adjustment ICU Study Pharmacist . Adherence study protocol maximize use guideline , interactive education , audit , feedback reminder . All patient bilateral low limb ultrasound within 48 hour ICU admission , twice weekly ICU discharge , upon clinical suspicion DVT , within 7 10 day ICU discharge . Patients positive indeterminant ultrasound proximal DVT confirmatory ascend contrast venography contraindication exist . We diagnose PE accord predefined diagnostic algorithm . We record bleed event , thrombocytopenia , HIT complication . Patients follow throughout hospital stay . Adjudication Committees blind data adjudicate indeterminant positive VTE test , test complication bleed event . We formally evaluate success feasibility objective use intention treat analysis Pilot Study . Primary Outcome : The primary outcome PROTECT Study objectively confirm proximal DVT ( prove symptomatic asymptomatic DVT ) diagnose bilateral low extremity compression ultrasound , confirm venography possible . Secondary Outcomes : There four secondary outcome : 1 ) PE diagnose PE Diagnosis algorithm , 2 ) bleeding , 3 ) anti-Xa level associate heparin dose adjustment , 4 ) thrombocytopenia HIT Relevance : Results PROTECT Pilot Study provide key feasibility safety data serve plan large multicentre trial LMWH versus UFH VTE prophylaxis medical-surgical ICU patient .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<criteria>1 . Admission ICU 2 . Men woman great 18 year age old 3 . Expected remain ICU admission great 72 hour 1 . Contraindications LMWH blood product 2 . Trauma , post orthopedic surgery , post cardiac surgery post neurosurgery patient , 3 . Uncontrolled hypertension define systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg , 4 . Hemorrhagic stroke , DVT , PE major hemorrhage admission within 3 month , 5 . Coagulopathy define INR &gt; 2 time upper limit normal [ ULN ] , PTT &gt; 2 time ULN , 6 . Renal insufficiency define creatinine clearance &lt; 30ml/min , 7 . A need oral intravenous subcutaneous therapeutic anticoagulation , 8 . Heparin allergy , proven suspect heparininduced thrombocytopenia ( HIT ) , 9 . Receipt &gt; 2 dos UFH LMWH ICU , 10 . Pregnant lactating , 11 . Withdrawal life support limitation life support , 12 . Prior enrollment trial 13 . Prior enrollment relate RCT 14 . Thrombocytopenia define platelet count &lt; 100 x 109/L , 15 . Bilateral low limb amputation , 16 . Allergy pork pork product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Critically Ill</keyword>
	<keyword>Deep Venous Thrombosis</keyword>
	<keyword>Randomized Control Trial</keyword>
	<keyword>Pilot Study</keyword>
</DOC>